business
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
Key takeaways
- ELVN On June 22, 2026, Orbimed Advisors, a 10% Owner of Enliven Therapeutics, Inc.
- Transaction value based on SEC Form 4 weighted average purchase price ($45.36); post-transaction value based on June 22, 2026 market close.
- * 1-year performance calculated using June 22nd, 2026 as the reference date.
ELVN On June 22, 2026, Orbimed Advisors, a 10% Owner of Enliven Therapeutics, Inc. (NASDAQ:ELVN), disclosed the indirect sale of 860,123 shares for a total transaction value of approximately $39.0 million, as reported in the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($45.36); post-transaction value based on June 22, 2026 market close.
What is the structure of Orbimed's ownership post-transaction?Following this transaction, all remaining 6,555,102 shares reported in the filing are held indirectly through OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop